A pilot safety trial of prolonged (48 h) infusion of the dual endothelin-receptor antagonist tezosentan in patients with advanced heart failure Academic Article Article uri icon

Overview

MeSH Major

  • Drug Utilization Review
  • Heart Failure
  • Practice Patterns, Physicians'
  • Registries
  • Ventricular Dysfunction, Left

abstract

  • Prolonged, 48-h IV dual endothelin-receptor antagonism with tezosentan was well tolerated with no new safety concerns emerging. These data further support the potential role of tezosentan in the treatment of patients with acute heart failure.

publication date

  • January 2001

Research

keywords

  • Academic Article

Identity

Digital Object Identifier (DOI)

  • 10.1378/chest.120.2.460

PubMed ID

  • 11502644

Additional Document Info

start page

  • 460

end page

  • 6

volume

  • 120

number

  • 2